MORPHIC HOLDING INC (MORF) Stock Price & Overview

NASDAQ:MORFUS61775R1059

Current stock price

56.99 USD
+0.02 (+0.04%)
At close:
56.99 USD
0 (0%)
After Hours:

The current stock price of MORF is 56.99 USD. Today MORF is up by 0.04%. In the past month the price increased by 1.19%. In the past year, price increased by 5.11%.

MORF Key Statistics

52-Week Range19.345 - 57
Current MORF stock price positioned within its 52-week range.
1-Month Range56.35 - 57
Current MORF stock price positioned within its 1-month range.
Market Cap
2.855B
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-3.75
Dividend Yield
N/A

MORF Stock Performance

Today
+0.04%
1 Week
+0.19%
1 Month
+1.19%
3 Months
+94.97%
Longer-term
6 Months +51.25%
1 Year +5.11%
2 Years +107.09%
3 Years -9.55%
5 Years +208.05%
10 Years N/A

MORF Stock Chart

MORPHIC HOLDING INC / MORF Daily stock chart

MORF Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to MORF. When comparing the yearly performance of all stocks, MORF is one of the better performing stocks in the market, outperforming 94.75% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

MORF Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to MORF. While MORF has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MORF Earnings

Next Earnings DateNov 1, 2024
Last Earnings DateJul 25, 2024
PeriodQ2 / 2024
EPS Reported-$1.15
Revenue Reported
EPS Surprise -15.97%
Revenue Surprise %

MORF Forecast & Estimates

15 analysts have analysed MORF and the average price target is 59.6 USD. This implies a price increase of 4.57% is expected in the next year compared to the current price of 56.99.

For the next year, analysts expect an EPS growth of -16.05% and a revenue growth -50.42% for MORF


Analysts
Analysts73.33
Price Target59.6 (4.58%)
EPS Next Y-16.05%
Revenue Next Year-50.42%

MORF Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

MORF Financial Highlights

Over the last trailing twelve months MORF reported a non-GAAP Earnings per Share(EPS) of -3.75. The EPS decreased by -15.74% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-179.82M
Industry RankSector Rank
PM (TTM) N/A
ROA -27.83%
ROE -29.08%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-25%
Sales Q2Q%N/A
EPS 1Y (TTM)-15.74%
Revenue 1Y (TTM)-100%

MORF Ownership

Ownership
Inst Owners1.36%
Shares50.09M
Float40.62M
Ins Owners15.53%
Short Float %N/A
Short RatioN/A

About MORF

Company Profile

MORF logo image Morphic Holding, Inc., operates as a biopharmaceutical company, which researches and develops oral small-molecule integrin therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2019-06-27. The firm is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The firm is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). The company has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.

Company Info

IPO: 2019-06-27

MORPHIC HOLDING INC

35 Gatehouse Drive A2

Waltham MASSACHUSETTS 02451 US

CEO: Praveen P. Tipirneni

Employees: 124

MORF Company Website

Phone: 17819960955

MORPHIC HOLDING INC / MORF FAQ

Can you describe the business of MORPHIC HOLDING INC?

Morphic Holding, Inc., operates as a biopharmaceutical company, which researches and develops oral small-molecule integrin therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2019-06-27. The firm is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The firm is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). The company has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.


What is the current price of MORF stock?

The current stock price of MORF is 56.99 USD. The price increased by 0.04% in the last trading session.


What is the dividend status of MORPHIC HOLDING INC?

MORF does not pay a dividend.


What is the ChartMill technical and fundamental rating of MORF stock?

MORF has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the market cap for MORPHIC HOLDING INC?

MORPHIC HOLDING INC (MORF) has a market capitalization of 2.85B USD. This makes MORF a Mid Cap stock.


Can you provide the ownership details for MORF stock?

You can find the ownership structure of MORPHIC HOLDING INC (MORF) on the Ownership tab.